Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Haifa Al-Ali"'
Autor:
Dietger Niederwieser, Dirk Hasenclever, Wolfgang Berdel, Bart J. Biemond, Haifa Al-Ali, Yves Chalandon, Michel van Gelder, Christian Junghanß, Gösta Gahrton, Mathias Hänel, Rüdiger Hehlmann, Thomas Heinicke, Andreas Hochhaus, Simona Iacobelli, Rien van Marwijk Kooy, Nicolaus Kröger, Jeroen Janssen, Madlen Jentzsch, Frank Breywisch, Mohamad Mohty, Stavroula Masouridi-Levrat, Gert Ossenkoppele, Jacob Passweg, Wolfram Pönisch, Johannes Schetelig, Christoph Schliemann, Sebastian Schwind, Matthias Stelljes, Leo F. Verdonck, Vladan Vucinic, Bob Löwenberg, Jan Cornelissen
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Given the selection of elderly patients with AML in first complete remission (CR1) the advantage of consolidation with allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed AML patients in CR1 aged
Externí odkaz:
https://doaj.org/article/e24e854d3915489f8bfdf3f02374efc6
Autor:
Sabine Neser, Antje Haas, Ralph Naumann, Erika Kettner, Robert Rohrberg, Kathrin Haifa Al-Ali, Ursula Haak, Michael Herold, Christian Klinkenstein, Astrid Franke, Mathias Freund, Gottfried Dölken, Ulrich Mey, Ullrich von Grünhagen, Michael Aβmann, Klaus Höffken, Stefanie Srock, Wolfgang Knauf, Thomas Ittel, Andreas Neubauer
Publikováno v:
Journal of Clinical Oncology. 25:1986-1992
Purpose Rituximab has been shown to be active in follicular lymphoma (FL), both as monotherapy and in combination with chemotherapy. We conducted a randomized trial comparing mitoxantrone, chlorambucil, and prednisolone (MCP) chemotherapy plus rituxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba5a75ad1f7f18a4a63fcdb50a725f2a
https://doi.org/10.1200/jco.2006.06.4618
https://doi.org/10.1200/jco.2006.06.4618
Autor:
Cornelia Becker, Simone Heyn, Lorenz Weidhase, Thomas Schliwa, Malvina Bourgeois, Yvonne Remane, Barbara Moll, Wolfram Pönisch, Marc Andrea, Dietger Niederwieser, Sirak Petros, Andreas Schwarzer, Vladan Vucinic, Rainer Krahl, Ute Kreibich, Anette Bachmann, Tom H. Lindner, Marion Schmalfeld, Runa Stiegler, Stefan Fricke, Haifa Al Ali, Matthias Egert, Franz Albert Hoffmann, Thomas Edelmann
Introduction Serious renal failure represents a severe complication of multiple myeloma (MM), with an estimated 25-50 % of patients being affected. Both bortezomib and bendamustine have been identified as quickly acting, effective and well-tolerated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65778d28f99f750100db5531ebe0b6e7
https://publica.fraunhofer.de/handle/publica/234515
https://publica.fraunhofer.de/handle/publica/234515
Autor:
Simone Heyn, Rainer Krahl, Ina Wagner, Barbara Moll, Wolfram Pönisch, Michael Aßmann, Robert Rohrberg, Andreas Schwarzer, Malvina Bourgeois, Gerald Hensel, Haifa Al Ali, Cornelia Becker, Thomas Zehrfeld, Martin Mohren, Uta Schönfelder, Thomas Edelmann, Marion Schmalfeld, Kerstin Löschcke, Nadja Jäkel, Dietger Niederwieser, Hans-Jürgen Hurtz, Franz Albert Hoffmann
Publikováno v:
Journal of cancer research and clinical oncology. 139(3)
Bortezomib (Velcade) is a proteasome inhibitor that has shown important clinical efficacy either as a single agent or in combination with other cytostatic agents in multiple myeloma (MM). In the present protocol, bortezomib was combined with other ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a6ca123ee519d08778666517cc05a02
https://pubmed.ncbi.nlm.nih.gov/23184429
https://pubmed.ncbi.nlm.nih.gov/23184429
Autor:
Irit, Avivi, Silvia, Montoto, Carme, Canals, John, Maertens, Haifa, Al-Ali, Ghulam J, Mufti, Jürgen, Finke, Anton, Schattenberg, Renato, Fanin, Jan J, Cornelissen, Jean-Paul, Vernant, Nigell, Russell, Yves, Beguin, Kirsty, Thomson, Leo F, Verdonck, Guido, Kobbe, Herve, Tilly, Gerard, Socié, Anna, Sureda, H, Tilly
Publikováno v:
British journal of haematology. 147(5)
Matched unrelated donor stem cell transplantation (MUD-SCT) provides the only curative option for patients with follicular lymphoma (FL) who fail conventional therapies and do not have a sibling donor. The purpose of this study was to analyse the out
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0940cf14be61d8e7a1056da2869002e7
https://pubmed.ncbi.nlm.nih.gov/19793383
https://pubmed.ncbi.nlm.nih.gov/19793383
Autor:
Hans Juergen Hurtz, Cornelia Becker, Leanthe Braunert, Andreas Schwarzer, Nadja Jaekel, Malvina Bourgeois, Song-Yau Wang, Dietger Niederwieser, Simone Heyn, Haifa Al Ali, Franz Albert Hoffmann, Wolfram Poenisch, Robert Rohrberg
Publikováno v:
Blood. 110:2723-2723
Introduction: Bortezomib is a novel proteasome inhibitor that has shown important clinical efficacy either as a single agent or in combination with other cytostatic agents in relapsed/refractory multiple myeloma (MM). The combinated treatment of bort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b93a7da69bc3d4e4b467ba2ef209f2be
https://doi.org/10.1182/blood.v110.11.2723.2723
https://doi.org/10.1182/blood.v110.11.2723.2723
Autor:
A. Gerhardt, Astrid Franke, Cornelia Becker, Michael Assmann, W. Helbig, Norbert Grobe, Ute Kreibich, Mathias Freund, Simone Heyn, Dietger Niederwieser, F. Fiedler, Gottfried Doelken, Thoralf Lange, Erika Kettner, Klaus Fenchel, Kristiane Senftleben, Antje Schulze, Axel Florschuetz, Thomas Ittel, Rainer Krahl, Bernhard Opitz, Wolfram Poenisch, Hans-Heinrich Wolf, Detlev Haehling, Michael Cross, Manfred Schulze, Ullrich Wedding, L Uharek, Norma Peter, Renate Huhn, Veronika Schirmer, Haifa Al Ali, Ernst Zschuppe, Niklas Zojer
Publikováno v:
Blood. 108:1921-1921
AML patients with unfavourable cytogenetics generally have a poor outcome. Over the last decade a number of strategies to improving survival have been assessed by the East German Study Group (OSHO). Here, we analyse the results of three protocols (AM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::599e36e2c41a454c8efc0b77726d48ba
https://doi.org/10.1182/blood.v108.11.1921.1921
https://doi.org/10.1182/blood.v108.11.1921.1921
Autor:
Heiner Wolf, Bernhard Opitz, Christian Klinkenstein, Mathias Freund, Johannes G. Meran, Rainer Krahl, Michael Assmann, Cornelia Becker, Rita Subert, Klaus Dachselt, Astrid Franke, Ute Hegenbart, W. U. Knauf, Renate Huhn, Wolfram Poenisch, Cornelia Winkelmann, Norma Peter, Veronika Schirmer, Haifa Al Ali, Ute Kreibich, Luisa Mantovani, Ernst Zschuppe, Ulrich Wedding, F. Fiedler, Michael Herold, Rita Pasold, Manfred Schulze, Dietger Niederwieser, Ursula Haak, W. Helbig, Thomas Ittel, Erika Kettner, Dirk Hasenclever, Norbert Grobe
Publikováno v:
Blood. 106:1851-1851
Outcome of elderly patients with AML is usually poor. Increased incidence of high risk AML and intolerance against dose escalation are the main causes for treatment failure. Pharmacokinetic measurements indicated that intracellular Ara-CTP formation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97574269341b29b4085cd578741475b9
https://doi.org/10.1182/blood.v106.11.1851.1851
https://doi.org/10.1182/blood.v106.11.1851.1851
Autor:
Karlheinz Merkle, Wolfram Poenisch, G. Gelbrich, Dietger Niederwieser, Stefanie Lehmann, Markus Loeffler, Dirk Hasenclever, Haifa Al Ali, Markus Hamel
Publikováno v:
Blood. 104:4861-4861
Introduction: It is well known that multiple myeloma (MM) is often associated with immunoglobulin (Ig) deficiency and increased risk of infection. We evaluated the Ig levels in 150 patients with MM stage II and III as part of a phase III randomised s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e2819128bc87b0ba545123a2bb302ca
https://doi.org/10.1182/blood.v104.11.4861.4861
https://doi.org/10.1182/blood.v104.11.4861.4861
Autor:
Ute Kreibich, Dietger Niederwieser, Cornelia Becker, Wolfram Poenisch, Thomas Ittel, Ursula Haak, Wolfgang Knauf, Rainer Krahl, Michael Assmann, W. Helbig, Dietrich Kaempfe, Johannes Meran, Norma Peter, Cornelia Winkelmann, Rita Pasold, Manfred Schulze, Erika Kettner, Ferdinand Fiedler, Norbert Grobe, Wolfgang Schultze, Juergen Steglich, Hans Heinrich Wolf, Ulrich Wedding, Veronika Schirmer, Haifa Al Ali, M. Freund, Bernhard Opitz, Manfred Herold, Rita Subert, Klaus Dachselt, Renate Huhn, Christian Klinkenstein
Publikováno v:
Blood. 104:880-880
Treatment of elderly patients (pts) with AML requires a sensitive balance between efficacy and toxicity. In the AML97 study all pts with AML > 60 years (y) were registered and, according to their clinical status, treated in curative, palliative or su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31bd50bf1f92d16cb07ef6ec47f8c52a
https://doi.org/10.1182/blood.v104.11.880.880
https://doi.org/10.1182/blood.v104.11.880.880